KalVista Pharmaceuticals (NASDAQ:KALV) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a report issued on Thursday morning,Benzinga reports. They currently have a $28.00 price objective on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Monday, October 7th.

KalVista Pharmaceuticals Stock Down 4.3 %

KALV stock opened at $9.06 on Thursday. The firm has a market capitalization of $391.36 million, a PE ratio of -2.57 and a beta of 0.85. KalVista Pharmaceuticals has a twelve month low of $7.39 and a twelve month high of $16.88. The stock’s 50 day moving average is $10.95 and its 200-day moving average is $11.83.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. On average, equities research analysts anticipate that KalVista Pharmaceuticals will post -2.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,400 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at $2,468,697.48. The trade was a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,016 shares of company stock worth $319,344. Insiders own 10.50% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. nVerses Capital LLC bought a new position in KalVista Pharmaceuticals in the 2nd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 67.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 3,328 shares during the period. Intech Investment Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the third quarter valued at $126,000. SG Americas Securities LLC bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $153,000. Finally, Quest Partners LLC purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth about $175,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).